Skip to content

Enforcement of the regional alliances with the convalescent hospital for the hemiparesis-patients with the brain disease in "the effective study of the function recovery treatment using RobotSuit HAL for the central motor dysfunction due to the cerebrospinal injury and a construction of the regional alliances function recovery treatment program"

Enforcement of the regional alliances with the convalescent hospital for the hemiparesis-patients with the brain disease in "the effective study of the function recovery treatment using RobotSuit HAL for the central motor dysfunction due to the cerebrospinal injury and a construction of the regional alliances function recovery treatment program" - Regional alliances of RobotSuit HAL treatment for patients with hemiparesis due to the brain disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024212
Enrollment
20
Registered
2016-10-01
Start date
2016-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

HAL treatment

Sponsors

University of Tsukuba
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Hemiparesis resulting from unilateral ischemic or hemorrhagic stroke in the acute phase. 2)Age:20-80 years old 3)Time since stroke onset within 7-14 days. 4)Functional Ambulation Category (FAC) 1-2 5)Patient can ensure more than 6 weeks from intervention initiation. 6)Patient with a score of more than 4 on the FAC prior to stroke. 7)Patient can consent by a document. If the handwriting is difficult due to the paralysis, it is assumed to obtain a document consent from ghost-writing user. 8)Patient who can be suitable for HAL

Exclusion criteria

Exclusion criteria: 1)It is difficult to perform the voluntary movement of the limbs in accordance with the instructions due to the disturbance of consciousness. 2)Patients has a complication, for example, severe cardiac disease and musculoskeletal system which can disturb the treatment using HAL. 3)Patients who investigator or sub investigator deemed inappropriate In this clinical trial. 4)Patients received magnetic stimulation, electrical stimulation and so no, neuromodulation therapy prior to the this study.

Design outcomes

Primary

MeasureTime frame
Adverse event Feasibility

Countries

Japan

Contacts

Public ContactAiki Marushima

Faculty of Medicine, University of Tsukuba Department of Neurosurgery, Department of Emergency and Critical Care Medicine

aiki.marushima@md.tsukuba.ac.jp029-853-3220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026